Business Segments Laboratorios Farmaceuticos Rovi, S.A. OTC Markets
Stocks
LABFF
ES0157261019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.86 USD | -27.31% |
|
-.--% | - |
| 13/05 | Spanish stocks - Factors to watch on May 13 | RE |
| 09/05 | Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026 |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Manufacturing | 47Cr | 62Cr | 64Cr | 60Cr | 49Cr | |||||
Total Assets | 37Cr | 64Cr | 77Cr | 79Cr | 92Cr | |||||
Interest Expense | - | - | - | 12.19L | 7L | |||||
Income Tax Expense | 3.54Cr | 5.28Cr | 4.96Cr | 4.38Cr | 3.96Cr | |||||
CAPEX | -3.52Cr | -4.93Cr | -5.12Cr | -5.94Cr | -5.94Cr | |||||
EBT | 17Cr | 24Cr | 24Cr | 21Cr | 20Cr | |||||
EBITDA | 18Cr | 26Cr | 25Cr | 23Cr | 22Cr | |||||
D&A | 1.11Cr | 1.42Cr | 1.52Cr | 1.88Cr | 2.1Cr | |||||
Operating Income | 17Cr | 24Cr | 24Cr | 21Cr | 20Cr | |||||
Net Income | 14Cr | 19Cr | 19Cr | 17Cr | 16Cr | |||||
Other | - | - | - | - | 99T | |||||
Total Assets | 5L | 5L | 10.4L | 21.62L | 54.3L | |||||
Interest Expense | - | - | - | -26T | 3L | |||||
Income Tax Expense | -9T | -3T | -9T | -18T | -2L | |||||
CAPEX | - | - | - | - | -8L | |||||
EBT | -49T | -12T | -82T | -2L | -14.15L | |||||
EBITDA | -49T | -12T | -76T | -2L | -15.85L | |||||
D&A | - | - | - | 21T | 1L | |||||
Operating Income | -49T | -12T | -76T | -2L | -17.22L | |||||
Net Income | -40T | -9T | -73T | -2L | -12.33L | |||||
Pharmaceutical Product Distribution | ||||||||||
Marketing | 38Cr | 41Cr | 42Cr | 43Cr | 47Cr | |||||
Total Assets | 49Cr | 49Cr | 46Cr | 48Cr | 54Cr | |||||
Interest Expense | - | - | - | 6.06Cr | 2.34Cr | |||||
Income Tax Expense | -49.24L | 58.26L | -10L | 6L | 34.79L | |||||
CAPEX | -98.27L | -64.51L | -97.7L | -61.28L | -1.37Cr | |||||
EBT | 3.96Cr | 1.64Cr | -2.26Cr | 4.21Cr | 2.34Cr | |||||
EBITDA | 2.35Cr | 2.28Cr | -1.18Cr | -93.03L | 93.79L | |||||
D&A | 1.02Cr | 87.24L | 91.49L | 92.68L | 93.94L | |||||
Operating Income | 1.32Cr | 1.41Cr | -2.1Cr | -1.86Cr | -15T | |||||
Net Income | 4.45Cr | 1.06Cr | -2.16Cr | 4.15Cr | 1.99Cr | |||||
Inter-Segment Transactions | -21Cr | -22Cr | -24Cr | -26Cr | -22Cr | |||||
Total Assets | -12Cr | -23Cr | -41Cr | -41Cr | -43Cr | |||||
Interest Expense | - | - | - | -6.35Cr | -2.7Cr | |||||
Income Tax Expense | -9L | -4L | 15.27L | -35.61L | -20T | |||||
EBT | -2.84Cr | -14.38L | 61.13L | -7.83Cr | -3.54Cr | |||||
EBITDA | -37.72L | -14.6L | 57.16L | -1.48Cr | -86.38L | |||||
D&A | - | -22T | -18T | -49T | -2L | |||||
Operating Income | -37.72L | -14.38L | 57.34L | -1.48Cr | -84.54L | |||||
Net Income | -2.75Cr | -10.73L | 45.86L | -7.48Cr | -3.54Cr | |||||
Total Assets | -94.89L | -1.89Cr | -2.64Cr | -3.2Cr | -8.22Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Spain | 26Cr | 26Cr | 27Cr | 28Cr | 29Cr | |||||
Total Assets | 65Cr | 82Cr | 74Cr | 77Cr | 89Cr | |||||
OECD Countries | 24Cr | 38Cr | 38Cr | 30Cr | 24Cr | |||||
European Union | 12Cr | 14Cr | 14Cr | 15Cr | 17Cr | |||||
Total Assets | 37.98L | 23.88L | 56.6L | 78.39L | 66.72L | |||||
Total Assets | 20.41L | 61.99L | 54.38L | 46.93L | 61.39L | |||||
Total Assets | 3.07Cr | 1.69Cr | 1.55Cr | 1.84Cr | 1.78Cr | |||||
Total Assets | 3.43Cr | 3.13Cr | 2.73Cr | 2.35Cr | 3.05Cr | |||||
Total Assets | 1.09Cr | 52.34L | 47.37L | 63L | 62.25L | |||||
Total Assets | 5L | 4L | 3L | 2L | 5T | |||||
Total Assets | - | 3L | 2L | 2L | 2L | |||||
Total Assets | - | - | - | - | 7L | |||||
Other Countries | 2.88Cr | 4.01Cr | 3.16Cr | 3.59Cr | 4.23Cr | |||||
Total Assets | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
